Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 25 | 26 | +1 |
| Shares | 4.81M | 4.23M | −584.0K (−12.1%) |
| Value | $14.6M | $11.8M | −$2.83M (−19.3%) |
New holders (4)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Toroso Investments, LLC | 24,657 | $69.0K | 0.00% |
| Millennium Management LLC | 13,036 | $36.0K | 0.00% |
| Royal Bank of Canada | 1,000 | $3.00K | 0.00% |
| UBS Group AG | 160 | $0 | 0.00% |
Sold out (3)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Jump Financial, LLC | 16,800 | $51.0K |
| Two Sigma Advisers, LP | 15,200 | $46.0K |
| Susquehanna Fundamental Investments, LLC | 10,200 | $31.0K |